Business
Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104
IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer Preclinical data package now includes animal studies showing
About this update from Immuneering Corporation
[{"type":"text","content":"IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer Preclinical data package now includes animal studies showing the potential for broad activity across tumors driven by MAPK pathway mutations including: KRAS-G12C, KRAS-G12D, KRAS-G12S, KRAS-G12V, NRAS-Q61R, and BRAF-V600E IMM-1-104 IND expected in Q3 2022; Enrollment of the first patient in Phase 1 testing expected in Q4 2022 CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today reported data in two preclinical abstracts at the 2022 ASCO Annual Meeting highlighting the pan-KRAS/NRAS activity of IMM-1-104. “These data underscore IMM-1-104's potential to broadly target solid tumors driven by a wide variety of frequently occurring KRAS and NRAS mutations. We believe IMM-1-104 focuses this pan-KRAS/NRAS activity selectively against malignant cells through its deep cyclic inhibition mechanism, which aims to deprive cancer cells of the sustained signaling they depend on to proliferate, while providing a cadenced release of inhibition that is designed to reduce the impact on healthy cells,” said Ben Zeskind, Ph.D., MBA, chief executive officer of Immuneering Corporation. “We look forward to submitting our IND for IMM-1-104 in the third quarter of 2022 and enrolling our first patient in the Phase 1 trial in the fourth quarter of 2022.” The abstracts reported are as follows: Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus sotorasib or adagrasib in KRAS mutant pancreatic tumors.Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary, publication onlyTrack: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryFirst author: Peter King, Ph.D. In this preclinical study, Immuneering researchers tested IMM-1-104 in a head-to-head comparison versus agents including sotorasib and adagrasib, in a series of preclinical models to characterize differential activity of each compound against pancreatic tumors driven by diverse KRAS mutations. Cell-based 2D biochemical and 3D growth assays were performed across nine pancreatic ductal adenocarcinoma (PDAC) models....